Hongwei Yang

Supplementary Table S5 from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial

Jieqiong Liu, Chengyang Song, Yaping Yang, Xiangcai Wang et autres

Supplemental table 5 Anti-HER2 treatment-related adverse events in patients

Supplementary Table S4 from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial

Jieqiong Liu, Chengyang Song, Yaping Yang, Xiangcai Wang et autres

Supplemental table 4 Immune-related adverse events (irAEs) in patients

Supplementary Table S3 from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial

Jieqiong Liu, Chengyang Song, Yaping Yang, Xiangcai Wang et autres

Supplemental table 3 Summary of the numbers of treatment discontinuations.

Data from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial

Jieqiong Liu, Chengyang Song, Yaping Yang, Xiangcai Wang et autres

AbstractPurpose: In this study, we report the results from a phase II trial assessing the safety and efficacy of KN046 in combination with KN026 in patients with HER2-positive metastatic breast cancer, who had progressed after prior anti-HER2 combination therapies. Patients and Methods: …

Supplementary Table S2 from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial

Jieqiong Liu, Chengyang Song, Yaping Yang, Xiangcai Wang et autres

Supplemental table 2 Sample size calculation.

Supplementary Data S1 from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial

Jieqiong Liu, Chengyang Song, Yaping Yang, Xiangcai Wang et autres

Trial protocol

Supplementary Table S1 from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial

Jieqiong Liu, Chengyang Song, Yaping Yang, Xiangcai Wang et autres

Supplemental table 1 Representativeness of study participants

Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial

Jieqiong Liu, Chengyang Song, Yaping Yang, Xiangcai Wang et autres

PURPOSE: In this study, we report the results from a phase II trial assessing the safety and efficacy of KN046 in combination with KN026 in patients with HER2-positive metastatic breast cancer, who had progressed after prior anti-HER2 combination therapies. PATIENTS AND METHODS: …

cn, us, Éthiopie (code pays fourni par la source)

Validation of Analytical Performance and Diagnostic Effectiveness of Anti-CCP Antibody Based on the Light-Initiated Chemiluminescence Assay.

Shizhen Guan, Hongjing Zhang, Yi Wang, Hongwei Yang et autres

OBJECTIVE: To evaluate the analytical and diagnostic performance of anti-cyclic citrullinated peptide (anti-CCP) antibody measured by the light-initiated chemiluminescence assay (LICA). METHODS: A total of 193 patients with rheumatoid arthritis (RA) and 211 controls were included. Serum anti-CCP levels were assessed by …

cn (code pays fourni par la source)

A novel tetranuclear Cu( ii ) complex for DNA-binding and in vitro anticancer activity

Shuhua Cao, Anlin Wang, Kaoxue Li, Zhiteng Lin et autres

A novel tetranuclear Cu(ii) complex (TNC) was successfully synthesized and characterized by X-ray single crystal diffraction. The interaction of the complex with calf thymus DNA (CT-DNA) has been studied by UV-vis absorption titration, fluorescence technology and molecular docking. The results indicated that …

cn (code pays fourni par la source)

Application of the Trivex system in the treatment of primary severe superficial varicose veins of the lower extremity

Wenshui Yu, Jing Liu, Hongwei Yang, Zuhui Wang et autres

PURPOSE: The aim of this study was to evaluate the clinical effects of the Trivex system in the treatment of primary severe superficial varicose veins of the lower extremity and compare Trivex to the point-form-stripping combined with foam sclerotherapy (FS). METHODS: A …

Risk Factor for Residue After Uterine Artery Chemotherapy and Embolization in Combination with Dilatation and Curettage for Treating Caesarean Scar Pregnancy

Feng Cheng, Dan Shan, Sijia Guo, Shuang Cheng et autres

OBJECTIVE: We aimed to investigate the potential risk factors for residual lesions after uterine artery chemotherapy and embolization (UACE) in combination with dilatation and curettage (D&C) in patients with cesarean scar pregnancy (CSP). SETTINGS: Retrospective case-control study. METHOD: Univariate analysis and logistic …

cn (code pays fourni par la source)